The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity.

The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity.

There are three prolyl hydroxylases (PHD1, 2 and 3) that regulate the hypoxia-inducible factors (HIFs), the master transcriptional regulators that respond to changes in intracellular O(2) tension. In high O(2) tension (normoxia) the PHDs hydroxylate two conserved proline residues on HIF-1α, which le...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Foxler, D, Bridge, K, James, V, Webb, T, Mee, M, Wong, S, Feng, Y, Constantin-Teodosiu, D, Petursdottir, T, Bjornsson, J, Ingvarsson, S, Ratcliffe, P, Longmore, G, Sharp, T
Format:	Journal article
Język:	English
Wydane:	2012

Podobne zapisy

Regulation of HIF: prolyl hydroxylases.
od: Stolze, I, i wsp.
Wydane: (2006)

The use of dioxygen by HIF prolyl hydroxylase (PHD1).
od: McNeill, L, i wsp.
Wydane: (2002)

Determination and comparison of specific activity of the HIF-prolyl hydroxylases.
od: Tuckerman, JR, i wsp.
Wydane: (2004)

2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase.
od: Mole, D, i wsp.
Wydane: (2003)

Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases.
od: Schlemminger, I, i wsp.
Wydane: (2003)

Characterization of different isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative initiation.
od: Tian, Y, i wsp.
Wydane: (2006)

Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates
od: Cockman, M, i wsp.
Wydane: (2019)

HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels.
od: Masson, N, i wsp.
Wydane: (2003)

Tuning the transcriptional response to hypoxia by inhibiting HIF prolyl- and asparaginyl-hydroxylases
od: Chan, M, i wsp.
Wydane: (2016)

Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases
od: Chowdhury, R, i wsp.
Wydane: (2016)

Molecular and Cellular Mechanisms of HIF Prolyl Hydroxylase inhibitors in Clinical Trials
od: Yeh, TL, i wsp.
Wydane: (2017)

Chemical basis for the selectivity of the von Hippel Lindau tumor suppressor pVHL for prolyl-hydroxylated HIF-1alpha.
od: Illingworth, C, i wsp.
Wydane: (2010)

The pVHL-hIF-1 system. A key mediator of oxygen homeostasis.
od: Maxwell, P, i wsp.
Wydane: (2001)

Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.
od: Hon, W, i wsp.
Wydane: (2002)

Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases.
od: Chowdhury, R, i wsp.
Wydane: (2013)

Tissue expression and functional insights into HIF prolyl hydroxylase domain enzymes
od: Wijeyekoon, JB
Wydane: (2013)

The HIF prolyl hydroxylase PHD3 is a potential substrate of the TRiC chaperonin.
od: Masson, N, i wsp.
Wydane: (2004)

Structural, biochemical and inhibition studies on hypoxia-inducible factor (HIF) prolyl hydroxylases
od: Lippl, K
Wydane: (2018)

Oxygen sensing by HIF hydroxylases.
od: Schofield, C, i wsp.
Wydane: (2004)

Signalling hypoxia by HIF hydroxylases.
od: Schofield, C, i wsp.
Wydane: (2005)

Effects of point mutations in pVHL on the binding of HIF-1α.
od: Domene, C, i wsp.
Wydane: (2012)

Effects of point mutations in pVHL on the binding of HIF-1α
od: Domene, C, i wsp.
Wydane: (2012)

Structure–activity relationship and crystallographic studies on 4-hydroxypyrimidine HIF prolyl hydroxylase domain inhibitors
od: Holt-Martyn, JP, i wsp.
Wydane: (2019)

Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion.
od: Yeoh, K, i wsp.
Wydane: (2013)

Prolyl hydroxylases and therapeutics.
od: Smith, T, i wsp.
Wydane: (2010)

The HIF hydroxylase pathway and the tumour microenvironment
od: Ratcliffe, P
Wydane: (2008)

HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation.
od: Willam, C, i wsp.
Wydane: (2006)

HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice.
od: Chen, R, i wsp.
Wydane: (2014)

HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice
od: Chen, R, i wsp.
Wydane: (2014)

Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway.
od: Giatromanolaki, A, i wsp.
Wydane: (2008)

Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway
od: Giatromanolaki, A, i wsp.
Wydane: (2008)

Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
od: Pollard, P, i wsp.
Wydane: (2006)

Expression of HIF-1a, HIF-2a (EPAS1), and their target genes in paraganglioma and phaeochromocytoma with VHL and SDH mutations
od: Pollard, P, i wsp.
Wydane: (2006)

Mutation Analysis of HIF-prolyl hydroxylases (PHD/EGLN) in Inherited Phaeochromocytoma and Renal Cell Carcinoma
od: Astuti, D, i wsp.
Wydane: (2010)

A fluorescent benzo[g]isoquinoline-based HIF prolyl hydroxylase inhibitor for cellular imaging
od: Mayer, M, i wsp.
Wydane: (2018)

Kinetic investigations of the oxygen entry pathway of the hypoxia-inducible factor (HIF) prolyl hydroxylase 2
od: Kearney, L
Wydane: (2015)

Substrate selectivity of prolyl hydroxylases
od: McDonough, M
Wydane: (2018)

Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility.
od: Astuti, D, i wsp.
Wydane: (2011)

The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia
od: Lawson, H, i wsp.
Wydane: (2024)

Hyperplasia of pulmonary neuroepithelial bodies (NEB) in lungs of prolyl hydroxylase -1(PHD-1) deficient mice
od: Pan, J, i wsp.
Wydane: (2012)